Evercore ISI analyst Liisa Bayko raised the firm’s price target on Travere Therapeutics to $30 from $12 and keeps an Outperform rating on the shares. The PARASOL workshop meeting was “favorable” for Travere, says Evercore, which thinks the company is more likely than not to get a nod from the FDA to file for expansion of Filspari into focal segmental glomerulosclerosis, or FSGS, on the basis of the existing Phase 3 DUPLEX dataset. Following the meeting, the firm has raised its view on the odds of success for the program to 60% from 10% and adjusted penetrance to 30%, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $25 from $17 at Wedbush
- Travere Therapeutics price target raised to $20 from $18 at BofA
- Travere Therapeutics price target raised to $41 from $23 at Guggenheim
- Travere Therapeutics price target raised to $18 from $14 at Barclays
- Travere Therapeutics price target lowered to $22 from $23 at Canaccord